Resveratrol
Polyphenol sirtuin activator found in red wine, studied extensively for cardiovascular and anti-aging effects.
Evidence Summary
A 2026 GRADE-assessed umbrella review in Nutrition Journal pooled 45 systematic reviews and 129 resveratrol-health associations. High-certainty evidence showed that in people with type 2 diabetes resveratrol lowered systolic blood pressure by about 7.97 mmHg and diastolic by about 3.55 mmHg versus placebo, reduced waist circumference by about 0.80 cm, and lowered total cholesterol by about 0.19 mmol/L in overweight adults. Moderate-certainty evidence supported improvements in glucose metabolism, renal function, endothelial function, working memory, hepatic steatosis and inflammation. A 2025 meta-analysis reported reductions in C-reactive protein and oxidative-stress markers in type 2 diabetes, though at low certainty. Benefits are most consistent in metabolically impaired populations. Importantly, a 2025 GRADE-assessed meta-analysis found no significant overall effect on human SIRT1, and effects on body weight, BMI and lipids in unselected or postmenopausal populations are generally null. No randomized trial has shown a benefit on human lifespan or hard clinical outcomes, and low oral bioavailability remains a key limitation. Educational information, not medical advice.
Evidence Scale
Mechanism of Action
Classically described as a SIRT1 and AMPK activator that partially mimics caloric restriction, with antioxidant, anti-inflammatory, mitochondrial and endothelial-supportive activity. However, a 2025 GRADE-assessed meta-analysis of randomized trials found no significant overall change in human SIRT1 expression, so the measurable clinical effects seen in trials (modest blood-pressure lowering, reduced C-reactive protein and oxidative-stress markers, improved glucose handling) likely act through vascular and anti-inflammatory pathways rather than robust sirtuin activation. Extensive first-pass metabolism gives trans-resveratrol low and variable oral bioavailability.
Who Is This For?
Cardiovascular support, anti-aging, metabolic health. Enhanced when combined with NAD+ precursors.
Protocol & Dosing
Dose
150-500mg daily trans-resveratrol.
Frequency
Daily with meals
Duration
Ongoing
Protocol Summary
Oral with fat-containing meal for absorption. Trans-resveratrol preferred. Often combined with NMN.
Latest Evidence
2024–2026: what the randomized-trial evidence actually shows
A 2026 umbrella review in Nutrition Journal synthesized 45 systematic reviews and 129 resveratrol–health associations, grading each with GRADE. Four reached high-certainty evidence: in people with type 2 diabetes, resveratrol lowered systolic blood pressure by 7.97 mmHg and diastolic by 3.55 mmHg versus placebo; across trials it reduced waist circumference by 0.80 cm; and in overweight adults it lowered total cholesterol by 0.19 mmol/L. Moderate-certainty evidence pointed to better glucose metabolism, renal function, endothelial function, working memory, hepatic steatosis and lower inflammation. A 2025 meta-analysis in Frontiers in Endocrinology found resveratrol significantly reduced C-reactive protein and oxidative-stress markers (lipid peroxides, 8-isoprostanes) in type 2 diabetes, though at low certainty. The signal is most consistent in metabolically impaired populations.
Context matters. A 2025 GRADE-assessed meta-analysis found no significant overall effect of resveratrol on human SIRT1 — the sirtuin its caloric-restriction-mimetic reputation rests on — and effects on body weight, BMI and lipids in unselected or postmenopausal groups are generally null. No randomized trial has shown a benefit on human lifespan or hard cardiovascular outcomes, and low oral bioavailability limits how much reaches the bloodstream. Resveratrol is best viewed as a modest metabolic and vascular adjunct — not a substitute for prescribed blood-pressure or glucose-lowering therapy. Use caution with anticoagulant or antiplatelet therapy and in hormone-sensitive conditions at higher doses. Educational information, not medical advice.
Umbrella review · 45 systematic reviews · GRADE high certainty · 2026
Resveratrol vs placebo: blood-pressure reduction in type 2 diabetes
Mean difference vs placebo (negative = reduction) with 95% confidence-interval whiskers. High-certainty (GRADE) pooled estimates in adults with type 2 diabetes, from an umbrella review of 45 systematic reviews and meta-analyses of randomized controlled trials. Source: Sun et al., Nutrition Journal (2026).
Related on Peak Human
Resveratrol (Supplement)
The paired supplement monograph: trans-resveratrol, forms, dosing and absorption.
NAD+ Precursors (NMN)
Frequently paired with resveratrol; the NAD+ biology and its evidence.
Type 2 Diabetes
Where resveratrol's randomized-trial evidence is strongest.
Hypertension
High-certainty blood-pressure reductions in type 2 diabetes.
Diagnostic Testing
Track blood pressure, glucose, lipids and inflammatory markers to guide use.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Resveratrol supplementation & multiple health outcomes: GRADE umbrella review of 45 systematic reviews — Nutrition Journal (2026) · Impact of resveratrol on human SIRT1: GRADE-assessed dose-response meta-analysis — J Acad Nutr Diet (2025) · Resveratrol on inflammation & oxidative stress in type 2 diabetes: meta-analysis — Frontiers in Endocrinology (2025) · Resveratrol & anthropometric indices in type 2 diabetes: meta-analysis — Phytotherapy Research (2025)
Interactions & Precautions
Contraindications
- Anticoagulant therapy (caution)
- Hormone-sensitive conditions (high doses)
Potential Risks
- •Bioavailability limitations
- •Drug interactions
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Trans-resveratrol is preferred over the cis form; there is mechanistic interest in pairing it with NMN or other NAD+ precursors; take with a fat-containing meal to aid absorption; pterostilbene is an alternative with better bioavailability. Recent randomized-trial evidence is strongest in type 2 diabetes and overweight or metabolically impaired adults, while benefits in healthy normometabolic people are less certain. Resveratrol is an adjunct, not a replacement for prescribed antihypertensive or glucose-lowering therapy. Use caution with anticoagulant or antiplatelet therapy and in hormone-sensitive conditions at higher doses.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation